There is a strong relationship between bivalirudin dosing requirements and renal function when steady state conditions are maintained, results of a study published in the September issue of Pharmacotherapy demonstrate.
There is a strong relationship between bivalirudin dosing requirements and renal function when steady state conditions are maintained, according to results of a study published in the September issue of Pharmacotherapy demonstrate.
Investigators conducted a retrospective medical record review to evaluate steady-state bivalirudin dosing requirements in patients with varying degrees of kidney function, as well as those receiving renal replacement therapy.
Study participants were identified through an administrative database at Main Medical Center, Portland, Me., Investigators identified the medical records for 64 adult patients, 18 years or older, who received at least 48 hours of bivalirudin therapy for known or suspected heparin-induced thrombocytopenia between March 2007 and May 2010. The patients were divided into 5 groups based on estimated kidney function according to Cockcroft-Gault–estimated creatinine clearance (Clcr) or by type of renal replacement therapy: 11 patients with Clcr less than 30 mL/minute, 21 patients with Clcr 30–60 mL/minute, 17 patients with Clcr greater than 60 mL/minute, 4 patients who received continuous venovenous hemofiltration (CVVH), and 4 patients who received hemodialysis.
The resulting data demonstrated that bivalirudin dosing requirements increased with increasing Clcr values. For the Clcr greater than 60 mL/minute cohort, the median bivalirudin dose was 0.15 mg/kg/hour, which was greater than median doses for Clcr 30–60 mL/minute (0.10 mg/kg/hr), Clcr less than 30 ml/minute (0.08 mg/kg/hr), CVVH (0.06 mg/kg/hr), and hemodialysis (0.04 mg/kg/hr). The median therapeutic bivalirudin dose was 0.09 mg/kg/hour (IQR 0.05–0.12 mg/kg/hr), and the median steady-state activated partial thromboplastin time value of 70 seconds (IQR 63–74 sec) was similar in all groups.
The authors note, “The high degree of variability in initial bivalirudin dosing requirements, particularly for patients with low Clcr values, suggests that individual patient dosing will require careful titration to achieve adequate anticoagulation.”
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More